Follow Us:
Primary care providers (physicians, nurse practitioners, and physician assistants) and neurologists, particularly community neurologists.
Diagnosis, Medicare Annual Wellness Visit, Cognitive Assessment Tools, Alzheimer’s Disease, Dementia, Cognitive, Functional, Behavioral, Mild Cognitive Impairment, Biomarkers
R. Scott Turner, MD, PhD
Director, Memory Disorders Program
Vice Chair for Clinical Research
Professor, Department of Neurology
Georgetown University Medical Center
Washington, DC
Eric G. Rodriguez, MD, MPH
Associate Professor of Medicine
University of Pittsburgh School of Medicine
Medical Director of Collaborative Care Management
University of Pittsburgh Medical Center
Pittsburgh, PA
1. | DESCRIBE the strengths and limitations of assessment tools used in clinical practice and clinical research settings for the screening and diagnosis of early AD | 2. | EMPLOY best clinical practices for the screening and diagnosis of early AD, including the use of validated clinical assessment tools |
1. | DESCRIBE the strengths and limitations of assessment tools used in clinical practice and clinical research settings for the screening and diagnosis of early AD |
2. | EMPLOY best clinical practices for the screening and diagnosis of early AD, including the use of validated clinical assessment tools |
SPONSORSHIP & SUPPORT
This educational activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Spire Learning.
This activity is supported by an independent educational grant from Biogen MA, Inc.
PROGRAM OVERVIEW
Alzheimer’s disease (AD) is the most common cause of dementia, with growing prevalence as the United States population ages. In older adults, the differences between normal age-related cognitive changes and the cognitive changes of Alzheimer’s dementia can be subtle; as such, the diagnosis of early AD requires clinicians to accurately assess and track patient cognition, function, and behavior over time through the effective use of validated assessment tools. However, despite modern clinical advancements evolving our understanding of AD, many patients with AD are either misdiagnosed or diagnosed late in the course of disease, and as a result may not be recognized for inclusion in ongoing clinical trials. Join our expert faculty as they provide you with key insights surrounding multiple unique patient scenarios designed to challenge your knowledge of available assessment tools for multiple domains of AD, while assessing their strengths, limitations, and suitability in different patient scenarios.
TARGET AUDIENCE
The target audience for this educational initiative is primary care providers (physicians, nurse practitioners, and physician assistants) and neurologists, particularly community neurologists.
LEARNING OBJECTIVES
Upon completion of this educational activity, learners should be better able to:
ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Spire Learning, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO RECEIVE CREDIT
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at JGoldman@akhcme.com.
CONFLICTS OF INTEREST STATEMENT
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The planners and faculty must disclose to the participants any significant relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients or with the commercial supporter of this accredited continuing education activity. Identified conflicts of interest are mitigated by AKH prior to the planners/faculty assuming their role in this accredited continuing education activity.
PLANNING COMMITTEE
R. Scott Turner, MD, PhD
Director, Memory Disorders Program
Vice Chair for Clinical Research
Professor, Department of Neurology
Georgetown University Medical Center
Washington, DC
Disclosures:
Researcher: Alector; Biogen; Eisai Inc; Eli Lilly and Co; Roche
CONTACT
If you have questions about this activity, please contact AKH Inc. at JGoldman@akhcme.com.
COURSE VIEWING REQUIREMENTS
Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
Additional Recommendations and Requirements | |
Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
Audio | - Microphone - Speakers or headphones - Audio recording support |
Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |